StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Regenxbio's profit margin for the twelve months ending Jun 30, 2026 was -112.6%. For fiscal 2025 it was -113.8%, against -272.5% the year before. The highest annual figure on record is 45.7% in fiscal 2018.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-113.8%+158.8
FY2024Dec 31, 2024-272.5%+19.4
FY2023Dec 31, 2023-292.0%−43.3
FY2022Dec 31, 2022-248.7%−275.9
FY2021Dec 31, 202127.2%+99.2
FY2020Dec 31, 2020-72.0%+196.9
FY2019Dec 31, 2019-268.9%−314.6
FY2018Dec 31, 201845.7%+749.8
FY2017Dec 31, 2017-704.0%+668.1
FY2016Dec 31, 2016-1372.1%−1071.5
FY2015Dec 31, 2015-300.6%−235.2
FY2014Dec 31, 2014-65.4%+23.1
FY2013Dec 31, 2013-88.5%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202621.0%+352.8
Q1 FY2026Mar 31, 2026-1408.6%−1415.4
Q4 FY2025Dec 31, 2025-221.3%+19.9
Q3 FY2025Sep 30, 2025-208.3%+38.0
Q2 FY2025Jun 30, 2025-331.8%−94.1
Q1 FY2025Mar 31, 20256.8%+412.2
Q4 FY2024Dec 31, 2024-241.3%+41.8
Q3 FY2024Sep 30, 2024-246.3%−32.3
Q2 FY2024Jun 30, 2024-237.7%+123.0
Q1 FY2024Mar 31, 2024-405.4%−57.0
Q4 FY2023Dec 31, 2023-283.1%−91.9
Q3 FY2023Sep 30, 2023-214.0%+70.7
Q2 FY2023Jun 30, 2023-360.7%−151.9
Q1 FY2023Mar 31, 2023-348.4%−3.1
Q4 FY2022Dec 31, 2022-191.2%−265.0
Q3 FY2022Sep 30, 2022-284.7%−94.9
Q2 FY2022Jun 30, 2022-208.8%+52.8
Q1 FY2022Mar 31, 2022-345.3%−79.8
Q4 FY2021Dec 31, 202173.8%+289.4
Q3 FY2021Sep 30, 2021-189.8%−198.7
Q2 FY2021Jun 30, 2021-261.6%−57.8
Q1 FY2021Mar 31, 2021-265.5%−38.6
Q4 FY2020Dec 31, 2020-215.6%+9.3
Q3 FY2020Sep 30, 20208.9%+244.2
Q2 FY2020Jun 30, 2020-203.8%−185.3
Q1 FY2020Mar 31, 2020-226.9%+3418.8
Q4 FY2019Dec 31, 2019-224.9%−235.4
Q3 FY2019Sep 30, 2019-235.3%+126.6
Q2 FY2019Jun 30, 2019-18.5%−45.0
Q1 FY2019Mar 31, 2019-3645.7%−3724.4
Q4 FY2018Dec 31, 201810.6%+794.7
Q3 FY2018Sep 30, 2018-361.9%+1188.0
Q2 FY2018Jun 30, 201826.5%+247.0
Q1 FY2018Mar 31, 201878.7%+4912.4
Q4 FY2017Dec 31, 2017-784.2%+372.0
Q3 FY2017Sep 30, 2017-1549.9%+12973.3
Q2 FY2017Jun 30, 2017-220.6%–
Q1 FY2017Mar 31, 2017-4833.6%–
Q4 FY2016Dec 31, 2016-1156.1%–
Q3 FY2016Sep 30, 2016-14523.2%–

More Regenxbio figures

See a number that looks wrong?